HOME > About us
WHO WE ARE

Founded in 2016, VJTBio Co., Ltd. (VJTBio) is an animal health company integrating the discovery, development, manufacturing, and commercialization of innovative veterinary drugs.

The company is committed to developing recombinant protein and antibody biopharmaceuticals for veterinary use. Our portfolio of pipelines includes more than ten innovative drugs covering the fields of livestock reproduction, disease prevention and control, and pet diseases, many of which received PCT patents and are recognized as first-in-class globally.

To date, we have filed approximately 100 invention patent applications in total and have been granted approximately 30 invention patents. In 2026 alone, we filed 28 invention patent applications and received 5 granted invention patents. The company maintains sustained investment in innovation and commits itself to building a robust intellectual property portfolio.

Global company footprint
Zhejiang GMP Manufacturing Base
Guangdong Office
Beijing Headquarters
Hangzhou Office
2016
Company founded
2016
Company founded
2018
Pipeline Development：Project VJT-101 obtained national clinical trial approval for New Veterinary Drugs
2018
Pipeline Development：Project VJT-101 obtained national clinical trial approval for New Veterinary Drugs
2020
Manufacturing Site： Started Construction
2020
Manufacturing Site： Started Construction
2020
Pipeline Advancement：Project VJT-102 entered clinical trials.
Project VJT-101 completed phase III clinical trials.
2020
Pipeline Advancement：Project VJT-102 entered clinical trials.
Project VJT-101 completed phase III clinical trials.
2021
Business Promotion：Formed marketing team for nationwide market promotion
2021
Business Promotion：Formed marketing team for nationwide market promotion
2021
Manufacturing Site：Started interior finishing and first phase of GMP plant construction
2021
Manufacturing Site：Started interior finishing and first phase of GMP plant construction
2022
Manufacturing Site：Completed construction
2022
Manufacturing Site：Completed construction
2023
Manufacturing Site：Completed GMP verification
2023
Manufacturing Site：Completed GMP verification
2024
Completed process validation for two projects
2024
Completed process validation for two projects
2025
Obtain National Class I New Veterinary Drug Certificate, Veterinary GMP Certificate and Veterinary Drug Production License
2025
Obtain National Class I New Veterinary Drug Certificate, Veterinary GMP Certificate and Veterinary Drug Production License
WHAT WE HAVE
01
GMP MANUFACTURING BASE
10,000 square-meter GMP manufacturing base with maximum annual culture volume of 20,000L (expandable to 40,000L) & GMP Manufacturing License.
02
EXPRESSION & LIBRARY PLATFORM
High-efficiency CHO cell protein expression platform, and natural antibody library and immune library derived from animal B cells.
03
ANTIBODY DISCOVERY PLATFORM
Antibody designing and screening platform covering drug discovery, bioactivity evaluation, and optimization.
04
REGULATORY & IP ADVANTAGE
National Class I and III New Veterinary Drug Certificates & PCT patents in major markets worldwide.
05
COMMERCIALIZATION & PIPELINE
First-in-class animal biopharmaceuticals approved for sale & pipeline products in development.
WHAT WE VALUE
OUR MISSION
OUR MISSION
For animals, For humanity; with reverence for life, devoted to making medicine.
OUR VISION
OUR VISION
To become a global leader in innovative veterinary drugs.
OUR VALUES
OUR VALUES
Committed to People's Well-being, Rooted in Dedication. Integrity, Diligence, Focus, Innovation.
FOUNDING TEAM
AWARDS & RECOGNITION
U.S. Patent
Australian Patent
Brazilian Patent
Canadian Patent
Russian Patent
New Zealand Patent
Mexican Patent
Chinese Patent - FSH fusion Protein
Chinese Patent - FSH‑CTP Fusion Protein
Chinese Patent - IFN‑λ1γ‑Fc(KiH) Fusion Protein
Chinese Patent - IL29
Chinese Patent - hCG
Chinese Patent -IFN‑λ1γ‑Fc fusion protein
Hong Kong Patent
Macao Patent